Redifferentiation  ||| S:0 E:18 ||| NNP
of  ||| S:18 E:21 ||| IN
iodine-refractory  ||| S:21 E:39 ||| FW
BRAF  ||| S:39 E:44 ||| FW
V600E-mutant  ||| S:44 E:57 ||| FW
metastatic  ||| S:57 E:68 ||| FW
papillary  ||| S:68 E:78 ||| FW
thyroid  ||| S:78 E:86 ||| FW
cancer  ||| S:86 E:93 ||| NN
with  ||| S:93 E:98 ||| IN
dabrafenib  ||| S:98 E:109 ||| VBG
To  ||| S:109 E:112 ||| TO
determine  ||| S:112 E:122 ||| VB
whether  ||| S:122 E:130 ||| IN
the  ||| S:130 E:134 ||| DT
selective  ||| S:134 E:144 ||| JJ
BRAF  ||| S:144 E:149 ||| NNP
inhibitor ||| S:149 E:158 ||| NN
,  ||| S:158 E:160 ||| ,
dabrafenib ||| S:160 E:170 ||| NN
,  ||| S:170 E:172 ||| ,
can  ||| S:172 E:176 ||| MD
stimulate  ||| S:176 E:186 ||| VB
radioiodine  ||| S:186 E:198 ||| JJ
uptake  ||| S:198 E:205 ||| NN
in  ||| S:205 E:208 ||| IN
BRAF  ||| S:208 E:213 ||| NNP
V600E-mutated  ||| S:213 E:227 ||| NNP
unresectable  ||| S:227 E:240 ||| NN
or  ||| S:240 E:243 ||| CC
metastatic  ||| S:243 E:254 ||| JJ
iodine-refractory  ||| S:254 E:272 ||| JJ
papillary  ||| S:272 E:282 ||| JJ
thyroid  ||| S:282 E:290 ||| JJ
cancer  ||| S:290 E:297 ||| NN
( ||| S:297 E:298 ||| -LRB-
PTC ||| S:298 E:301 ||| NNP
) ||| S:301 E:302 ||| -RRB-
.  ||| S:302 E:304 ||| .
Ten  ||| S:304 E:308 ||| CD
patients  ||| S:308 E:317 ||| NNS
with  ||| S:317 E:322 ||| IN
BRAF  ||| S:322 E:327 ||| NNP
V600E-mutant  ||| S:327 E:340 ||| NNP
iodine-refractory  ||| S:340 E:358 ||| NNP
PTC  ||| S:358 E:362 ||| NNP
were  ||| S:362 E:367 ||| VBD
enrolled ||| S:367 E:375 ||| VBN
.  ||| S:375 E:377 ||| .
Absence  ||| S:377 E:385 ||| NN
of  ||| S:385 E:388 ||| IN
radioiodine  ||| S:388 E:400 ||| JJ
uptake  ||| S:400 E:407 ||| NN
on  ||| S:407 E:410 ||| IN
iodine-131  ||| S:410 E:421 ||| CD
whole  ||| S:421 E:427 ||| JJ
body  ||| S:427 E:432 ||| NN
scan  ||| S:432 E:437 ||| VBZ
obtained  ||| S:437 E:446 ||| VBN
within  ||| S:446 E:453 ||| IN
14  ||| S:453 E:456 ||| CD
months  ||| S:456 E:463 ||| NNS
of  ||| S:463 E:466 ||| IN
study  ||| S:466 E:472 ||| NN
entry  ||| S:472 E:478 ||| NN
was  ||| S:478 E:482 ||| VBD
required ||| S:482 E:490 ||| VBN
.  ||| S:490 E:492 ||| .
Each  ||| S:492 E:497 ||| DT
patient  ||| S:497 E:505 ||| NN
received  ||| S:505 E:514 ||| VBD
dabrafenib  ||| S:514 E:525 ||| NNS
( ||| S:525 E:526 ||| -LRB-
150  ||| S:526 E:530 ||| CD
mg  ||| S:530 E:533 ||| NNS
twice  ||| S:533 E:539 ||| RB
daily ||| S:539 E:544 ||| JJ
)  ||| S:544 E:546 ||| -RRB-
for  ||| S:546 E:550 ||| IN
25  ||| S:550 E:553 ||| CD
days  ||| S:553 E:558 ||| NNS
before  ||| S:558 E:565 ||| IN
thyrotropin  ||| S:565 E:577 ||| JJ
Î±-stimulated  ||| S:577 E:590 ||| JJ
iodine-131  ||| S:590 E:601 ||| CD
whole  ||| S:601 E:607 ||| JJ
body  ||| S:607 E:612 ||| NN
scan  ||| S:612 E:617 ||| NNS
( ||| S:617 E:618 ||| -LRB-
4  ||| S:618 E:620 ||| CD
mCi ||| S:620 E:623 ||| JJ
/ ||| S:623 E:624 ||| CD
148  ||| S:624 E:628 ||| CD
MBq ||| S:628 E:631 ||| NN
) ||| S:631 E:632 ||| -RRB-
.  ||| S:632 E:634 ||| .
Patients  ||| S:634 E:643 ||| NNS
whose  ||| S:643 E:649 ||| WP$
scan  ||| S:649 E:654 ||| NNS
showed  ||| S:654 E:661 ||| VBD
new  ||| S:661 E:665 ||| JJ
sites  ||| S:665 E:671 ||| NNS
of  ||| S:671 E:674 ||| IN
radioiodine  ||| S:674 E:686 ||| JJ
uptake  ||| S:686 E:693 ||| NN
remained  ||| S:693 E:702 ||| VBD
on  ||| S:702 E:705 ||| IN
dabrafenib  ||| S:705 E:716 ||| NN
for  ||| S:716 E:720 ||| IN
17  ||| S:720 E:723 ||| CD
more  ||| S:723 E:728 ||| JJR
days ||| S:728 E:732 ||| NNS
,  ||| S:732 E:734 ||| ,
and  ||| S:734 E:738 ||| CC
then  ||| S:738 E:743 ||| RB
were  ||| S:743 E:748 ||| VBD
treated  ||| S:748 E:756 ||| VBN
with  ||| S:756 E:761 ||| IN
150  ||| S:761 E:765 ||| CD
mCi  ||| S:765 E:769 ||| NNS
( ||| S:769 E:770 ||| -LRB-
5.5  ||| S:770 E:774 ||| CD
GBq ||| S:774 E:777 ||| NN
)  ||| S:777 E:779 ||| -RRB-
iodine-131 ||| S:779 E:789 ||| NNP
.  ||| S:789 E:791 ||| .
The  ||| S:791 E:795 ||| DT
primary  ||| S:795 E:803 ||| JJ
endpoint  ||| S:803 E:812 ||| NN
of  ||| S:812 E:815 ||| IN
the  ||| S:815 E:819 ||| DT
study  ||| S:819 E:825 ||| NN
was  ||| S:825 E:829 ||| VBD
the  ||| S:829 E:833 ||| DT
percentage  ||| S:833 E:844 ||| NN
of  ||| S:844 E:847 ||| IN
patients  ||| S:847 E:856 ||| NNS
with  ||| S:856 E:861 ||| IN
new  ||| S:861 E:865 ||| JJ
radioiodine  ||| S:865 E:877 ||| JJ
uptake  ||| S:877 E:884 ||| NN
after  ||| S:884 E:890 ||| IN
treatment  ||| S:890 E:900 ||| NN
with  ||| S:900 E:905 ||| IN
dabrafenib ||| S:905 E:915 ||| NN
.  ||| S:915 E:917 ||| .
Six  ||| S:917 E:921 ||| CD
of  ||| S:921 E:924 ||| IN
10  ||| S:924 E:927 ||| CD
patients  ||| S:927 E:936 ||| NNS
( ||| S:936 E:937 ||| -LRB-
60 ||| S:937 E:939 ||| CD
% ||| S:939 E:940 ||| NN
)  ||| S:940 E:942 ||| -RRB-
demonstrated  ||| S:942 E:955 ||| VBD
new  ||| S:955 E:959 ||| JJ
radioiodine  ||| S:959 E:971 ||| JJ
uptake  ||| S:971 E:978 ||| NN
on  ||| S:978 E:981 ||| IN
whole  ||| S:981 E:987 ||| JJ
body  ||| S:987 E:992 ||| NN
scan  ||| S:992 E:997 ||| NN
after  ||| S:997 E:1003 ||| IN
treatment  ||| S:1003 E:1013 ||| NN
with  ||| S:1013 E:1018 ||| IN
dabrafenib ||| S:1018 E:1028 ||| NN
.  ||| S:1028 E:1030 ||| .
All  ||| S:1030 E:1034 ||| DT
6  ||| S:1034 E:1036 ||| CD
were  ||| S:1036 E:1041 ||| VBD
treated  ||| S:1041 E:1049 ||| VBN
with  ||| S:1049 E:1054 ||| IN
5.5  ||| S:1054 E:1058 ||| CD
GBq  ||| S:1058 E:1062 ||| JJ
iodine-131 ||| S:1062 E:1072 ||| NN
.  ||| S:1072 E:1074 ||| .
Two  ||| S:1074 E:1078 ||| CD
patients  ||| S:1078 E:1087 ||| NNS
had  ||| S:1087 E:1091 ||| VBD
partial  ||| S:1091 E:1099 ||| JJ
responses  ||| S:1099 E:1109 ||| NNS
and  ||| S:1109 E:1113 ||| CC
4  ||| S:1113 E:1115 ||| CD
patients  ||| S:1115 E:1124 ||| NNS
had  ||| S:1124 E:1128 ||| VBD
stable  ||| S:1128 E:1135 ||| JJ
disease  ||| S:1135 E:1143 ||| NN
on  ||| S:1143 E:1146 ||| IN
standard  ||| S:1146 E:1155 ||| JJ
radiographic  ||| S:1155 E:1168 ||| JJ
restaging  ||| S:1168 E:1178 ||| NN
at  ||| S:1178 E:1181 ||| IN
3  ||| S:1181 E:1183 ||| CD
months ||| S:1183 E:1189 ||| NNS
.  ||| S:1189 E:1191 ||| .
Thyroglobulin  ||| S:1191 E:1205 ||| NNP
decreased  ||| S:1205 E:1215 ||| VBD
in  ||| S:1215 E:1218 ||| IN
4  ||| S:1218 E:1220 ||| CD
of  ||| S:1220 E:1223 ||| IN
6  ||| S:1223 E:1225 ||| CD
treated  ||| S:1225 E:1233 ||| CD
patients ||| S:1233 E:1241 ||| NNS
.  ||| S:1241 E:1243 ||| .
One  ||| S:1243 E:1247 ||| CD
patient  ||| S:1247 E:1255 ||| NN
developed  ||| S:1255 E:1265 ||| VBD
squamous  ||| S:1265 E:1274 ||| JJ
cell  ||| S:1274 E:1279 ||| NN
carcinoma  ||| S:1279 E:1289 ||| NN
of  ||| S:1289 E:1292 ||| IN
the  ||| S:1292 E:1296 ||| DT
skin ||| S:1296 E:1300 ||| NN
.  ||| S:1300 E:1302 ||| .
There  ||| S:1302 E:1308 ||| EX
were  ||| S:1308 E:1313 ||| VBD
no  ||| S:1313 E:1316 ||| DT
other  ||| S:1316 E:1322 ||| JJ
significant  ||| S:1322 E:1334 ||| JJ
adverse  ||| S:1334 E:1342 ||| JJ
events  ||| S:1342 E:1349 ||| NNS
attributed  ||| S:1349 E:1360 ||| VBD
to  ||| S:1360 E:1363 ||| TO
dabrafenib ||| S:1363 E:1373 ||| VB
.  ||| S:1373 E:1375 ||| .
Dabrafenib  ||| S:1375 E:1386 ||| NNP
can  ||| S:1386 E:1390 ||| MD
stimulate  ||| S:1390 E:1400 ||| VB
radioiodine  ||| S:1400 E:1412 ||| JJ
uptake  ||| S:1412 E:1419 ||| NN
in  ||| S:1419 E:1422 ||| IN
patients  ||| S:1422 E:1431 ||| NNS
with  ||| S:1431 E:1436 ||| IN
metastatic  ||| S:1436 E:1447 ||| JJ
BRAF  ||| S:1447 E:1452 ||| NNP
V600E-mutant  ||| S:1452 E:1465 ||| NNP
iodine-refractory  ||| S:1465 E:1483 ||| NNP
PTC ||| S:1483 E:1486 ||| NNP
,  ||| S:1486 E:1488 ||| ,
representing  ||| S:1488 E:1501 ||| VBG
a  ||| S:1501 E:1503 ||| DT
potential  ||| S:1503 E:1513 ||| JJ
new  ||| S:1513 E:1517 ||| JJ
therapeutic  ||| S:1517 E:1529 ||| JJ
approach  ||| S:1529 E:1538 ||| NN
for  ||| S:1538 E:1542 ||| IN
these  ||| S:1542 E:1548 ||| DT
patients ||| S:1548 E:1556 ||| NNS
.  ||| S:1556 E:1558 ||| .
